Ischemic CardiomyopathyNCT05674955
CWT Versus AT on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.
A study testing Circuit weight versus aerobic training in people with Ischemic Cardiomyopathy, run by Cairo University at 1 site in Egypt.
Trial summary
To compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy. Read more about this study
- Who is it for?
- Ages 45 to 55 years, men only
- Conditions the study is for
- Ischemic Cardiomyopathy
- What is being tested?
- Circuit weight versus aerobic training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Aug 2024to 25 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 55 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Sixty male patients with ischemic cardiomyopathy as a result of a recent acute myocardial infarction event (≤2 months) with 40%<LVEF<50%.
- They are functionally classified as class II according to New York Heart Association (NYHA).
- Their age will be ranged from 45 to 55 years old.
- Their BMI will be ranged from 25 to 29.9 kg/m².
- They will have good mentality.
Who cannot join
- Recurrent coronary heart disease.
- Severe valvular diseases.
- Underlying pulmonary disease (aspiration pneumonia, chronic obstructive pulmonary disease, pneumothorax, etc.).
- Inability to ambulate owing to physical problems (paresis induced by cerebral stroke, spinal cord injury, amputation, severe pain, dyspnea, etc.).
- muskloskletal problems (e.g. severe osteoarthritis or ankylosing spondylitis).
- Impaired cognitive function (vascular dementia, Alzheimer's dementia, other psychological disease, etc.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Circuit Weight Versus Aerobic Training on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.
To compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.
Read the detailed description
Ischemic cardiomyopathy (ICM) is a term that refers to the heart's decreased ability to pump blood properly due to myocardial damage brought upon by ischemia. Ischemic cardiomyopathy has a spectrum of clinical changes which eventually leads to congestive heart failure (CHF). Initially, there is a reversible loss of cardiac contractile function because of decreased oxygen supply to the heart muscle; however, when there is ischemia for a prolonged period, there is irreversible cardiac muscle damage resulting in cardiac remodeling. Remodeling is primarily achieved by myocardial fibrosis which results in decreased cardiac function, arrhythmia, and possible cardiac conduction system impairment. In ischemic cardiomyopathy, there is a significant impairment of the left ventricular systolic function, with a left ventricular ejection fraction (LVEF) less than 40% (Bhandari et al., 2021).
- Conditions
- Ischemic Cardiomyopathy
- Being tested
- Circuit weight versus aerobic training
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Circuit weight versus aerobic trainingDiagnostic test
Circuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014)
B- Aerobic training:
This mode of exercise will be conducted for study group B as follows:
Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises.
Frequency: Three times / week (Nishi et al., 2011).
C-Traditional medical treatment:
This treatment will be conducted for all group A, B and C.
| Study group | Role | What they receive |
|---|---|---|
| Circuit weight group | Experimental | Not described Receives: Diagnostic Test: Circuit weight versus aerobic training |
| Aerobic group | Experimental | Not described Receives: Diagnostic Test: Circuit weight versus aerobic training |
| Control Group | Experimental | Not described Receives: Diagnostic Test: Circuit weight versus aerobic training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ejection fraction
Will be measured by precentge
Measured: 2 months
Secondary outcomes (1)
Blood pressure
Will be measured by mmhg
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2023
- Study start25 Aug 2024
- Primary completion25 Oct 2024
- Study completion25 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ischemic CardiomyopathyStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 3 groups of ischemic cardiomyopathy patients. 1st group receive circuit weight training. 2nd group receive aerobic. 3rd group receive medications
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Samira Shukrey Shaffik Eshak, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05674955
- Sponsor's protocol ID
- Cw versus AT in cardiomyopathy
- Status last verified
- Jul 2025
- First submitted
- 10 Dec 2022
- Last updated
- 10 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nishi I, Noguchi T, Iwanaga Y, Furuichi S, Aihara N, Takaki H, Goto Y. Effects of exercise training in patients with chronic heart failure and advanced left ventricular systolic dysfunction receiving beta-blockers. Circ J. 2011;75(7):1649-55. doi: 10.1253/circj.cj-10-0899. Epub 2011 May 25.
PubMed 21613745
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Circuit Weight Versus Aerobic Training on Selected Cardiovascular Indices and Functional Capacity in Patients With Ischemic Cardiomyopathy.
- ClinicalTrials.gov ID
- NCT05674955
- Acronym / sponsor ID
- Cw versus AT in cardiomyopathy
- Conditions
- Ischemic Cardiomyopathy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 25 Aug 2024 (actual)
- Primary completion
- 25 Oct 2024 (actual)
- Study completion
- 25 Oct 2024 (actual)
- First posted
- 9 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.
Detailed description
Ischemic cardiomyopathy (ICM) is a term that refers to the heart's decreased ability to pump blood properly due to myocardial damage brought upon by ischemia. Ischemic cardiomyopathy has a spectrum of clinical changes which eventually leads to congestive heart failure (CHF). Initially, there is a reversible loss of cardiac contractile function because of decreased oxygen supply to the heart muscle; however, when there is ischemia for a prolonged period, there is irreversible cardiac muscle damage resulting in cardiac remodeling. Remodeling is primarily achieved by myocardial fibrosis which results in decreased cardiac function, arrhythmia, and possible cardiac conduction system impairment. In ischemic cardiomyopathy, there is a significant impairment of the left ventricular systolic function, with a left ventricular ejection fraction (LVEF) less than 40% (Bhandari et al., 2021).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- 3 groups of ischemic cardiomyopathy patients. 1st group receive circuit weight training. 2nd group receive aerobic. 3rd group receive medications
| Arm | Type | Receives |
|---|---|---|
| Circuit weight group | Experimental | Diagnostic Test: Circuit weight versus aerobic training |
| Aerobic group | Experimental | Diagnostic Test: Circuit weight versus aerobic training |
| Control Group | Experimental | Diagnostic Test: Circuit weight versus aerobic training |
Who may qualify
- Ages
- 45 to 55 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Sixty male patients with ischemic cardiomyopathy as a result of a recent acute myocardial infarction event (≤2 months) with 40%<LVEF<50%.
- They are functionally classified as class II according to New York Heart Association (NYHA).
- Their age will be ranged from 45 to 55 years old.
- Their BMI will be ranged from 25 to 29.9 kg/m².
- They will have good mentality.
Key exclusion criteria (6 listed)
- Recurrent coronary heart disease.
- Severe valvular diseases.
- Underlying pulmonary disease (aspiration pneumonia, chronic obstructive pulmonary disease, pneumothorax, etc.).
- Inability to ambulate owing to physical problems (paresis induced by cerebral stroke, spinal cord injury, amputation, severe pain, dyspnea, etc.).
- muskloskletal problems (e.g. severe osteoarthritis or ankylosing spondylitis).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Circuit weight versus aerobic trainingCircuit weight :Duration: 30 min-60 min (total session) Frequency: 3 times / week. Intensity: increased load was established when subject was able to complete 12 repetitions ( Wayne, 2014) B- Aerobic training: This mode of exercise will be conducted for study group B as follows: Intensity: started by 60-85% of target heart rate according to each patient response Target heart rate (THR) = 60% -85% (maximum heart rate-resting heart rate) + resting heart rate Maximum heart rate (MHR) = (220-Age). Mode: Walking on treadmill. Duration: Each session consisted of 10 minutes warming up firstly then 30 minutes time of session ended by 10 minutes cool down exercises. Frequency: Three times / week (Nishi et al., 2011). C-Traditional medical treatment: This treatment will be conducted for all group A, B and C. | Diagnostic test | Aerobic group, Circuit weight group, Control Group |
Primary outcome
Ejection fraction
Time frame: 2 months
Will be measured by precentge
1 secondary outcome
Blood pressure
Time frame: 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2025.
- Results publication: PubMed 21613745Nishi I, Noguchi T, Iwanaga Y, Furuichi S, Aihara N, Takaki H, Goto Y. Effects of exercise training in patients with chronic heart failure and advanced left ventricular systolic dysfunction receiving beta-blockers. Circ J. 2011;75(7):1649-55. doi: 10.1253/circj.cj-10-0899. Epub 2011 May 25.
Related trials for Ischemic Cardiomyopathy
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Not yet recruitingPhase 2
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
Not yet recruiting
MRI-guided Ventricular Tachycardia Ablation in Patients With Structural Heart Disease
Ventricular Tachycardia (VT), Ischemic Cardiomyopathy
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Circuit weight versus aerobic training in people with Ischemic Cardiomyopathy, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ejection fraction (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05674955, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2025.